Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis 2021-02-26T19:14:23-08:00November 14th, 2016|2016 Press Releases, Press Releases| Read more
Ion Torrent Developers Alliance Program Designed to Speed Targeted NGS Assay Development 2021-02-26T19:14:30-08:00May 31st, 2016|2016 Press Releases, Press Releases| Read more
German Supreme Court Upholds and Strengthens Invivoscribe FLT3 Patent Position 2026-10-26T12:22:46-07:00March 28th, 2016|2016 Press Releases, Press Releases| Read more
Novartis drug PKC412 (midostaurin) receives Breakthrough Therapy designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia (AML) 2021-02-26T19:14:49-08:00February 18th, 2016|2016 Press Releases, Press Releases| Read more
Invivoscribe Announces Long-Term Collaboration to Develop Immuno-Oncology Tests With Thermo Fisher Scientific 2026-10-21T19:23:59-07:00February 9th, 2016|2016 Press Releases, Press Releases| Read more
